Government entities threw CV specialists for a loop in 2025 with changes that will inevitably affect patient care.

New evidence for treatment of pulmonary embolism, asymptomatic carotid stenosis, and CLTI led the way in 2025.

The Volt pulsed-field ablation (PFA) system (Abbott) has been approved by the US Food and Drug Administration for the treatment of patients with atrial fibrillation (AF), according to a Monday ...

Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

Health-related social needs in HF, removing age from frailty scores, CIED concerns about smartwatches, and more.

The prospective data indicate that clinicians should be aggressive with lipid-lowering therapies in these patients, experts say.

As research continues into how AI will impact practice, there are open questions about medical training, regulation, and more ...

In 2025, cardiology delved deeper into sex-specific risk factors and how to leverage them in prevention, Stacey Rosen says.

After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration.